TY - JOUR T1 - Rheumatological adverse events secondary to immune checkpoint inhibitors JO - Reumatología Clínica (English Edition) T2 - AU - Garbarino,María Cecilia AU - Manzano,Natalia AU - Messina,Osvaldo AU - Zylberman,Marcelo SN - 21735743 M3 - 10.1016/j.reumae.2023.03.001 DO - 10.1016/j.reumae.2023.03.001 UR - https://reumatologiaclinica.org/en-rheumatological-adverse-events-secondary-immune-articulo-S217357432300028X AB - The first experiences with a group of drugs called immune checkpoint inhibitors for the treatment of cancer were described in 2010. They are currently used in many tumours, with successful survival outcomes but a new profile of adverse events. This new spectrum of immune-mediated toxicities includes an exaggerated inflammatory response of T lymphocyte and the development of autoimmune diseases or similar pathologies. Of these, of particular note are the rheumatological toxicities. This review aims to alert internists and rheumatologists to their recognition and clinical management. ER -